FRED G. CONRAD; WILLIAM L. BRENEMAN; DOROTHY B. GRISHAM, B.S.
Since Rosenthal, Dreskin, and Rosenthal (1) first described plasma thromboplastin antecedent (PTA) deficiency 10 years ago, investigators from numerous hematology centers have emphasized the infrequent occurrence of this defect. Reports of the relative rate of occurrence of patients deficient in antihemophilic factor (AHF) and plasma thromboplastin component (PTC) are remarkably stable at a 4 to 1 ratio in this country and throughout the world (2-4). The reports of relative occurrence of PTA show marked variations from less than 1% to 18% of the total thromboplastinogen disorders (5-8).
Contrary to the usually reported low incidence, our studies indicate that PTA deficiency
CONRAD FG, BRENEMAN WL, GRISHAM DB. A Clinical Evaluation of Plasma Thromboplastin Antecedent (PTA) Deficiency. Ann Intern Med. ;62:885–898. doi: 10.7326/0003-4819-62-5-885
Download citation file:
Published: Ann Intern Med. 1965;62(5):885-898.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use